Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE) [Phase 2]
A Phase 2 Core OLE study of rodatristat ethyl in patients with pulmonary arterial hypertension has completed, and results were posted on 202…
-
FDA approval · 2025-06-03FDA Approved: EPOPROSTENOL — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves a supplemental application for epoprostenol submitted by Sun Pharmaceutical Industries, Inc., under the ANDA. The action update…
-
CLINICAL_TRIALS research · 2025-05-31Clinical Trial Update: Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH [Phase 3]
Phase 3 trial evaluating the safety and tolerability of treprostinil in children with pulmonary arterial hypertension is currently recruitin…
-
CLINICAL_TRIALS trial_result · 2025-05-30Clinical Trial Update: A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults [Phase 1]
A Phase 1 clinical trial evaluating HS135 for pulmonary arterial hypertension in adults has been terminated.
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: Study Roles of Heavy Metals and Essential Metal Dyshomeostasis in Pulmonary Arterial Hypertension Patients
A clinical trial investigating the role of heavy metals and metal homeostasis in patients with pulmonary arterial hypertension is currently …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-05-23FDA Approved: YUTREPIA — Original Application (Liquidia Technologies, Inc.)
FDA approved YUTREPIA (treprostinil) from Liquidia Technologies as an original application for the treatment of pulmonary arterial hypertens…
-
CLINICAL_TRIALS research · 2025-05-23Clinical Trial Update: Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension [NA]
This clinical trial update reports on ambrisentan for early low-risk pulmonary arterial hypertension, with the study currently not recruitin…
-
CLINICAL_TRIALS research · 2025-05-21Clinical Trial Update: China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization
A clinical trial update from China-Japan Friendship Hospital on a study for the diagnosis and management of pulmonary vascular disease using…
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension [Phase 2]
Phase 2 study of the investigational drug LTP001 in pulmonary arterial hypertension was terminated, with results posted.
-
CLINICAL_TRIALS research · 2025-05-15Clinical Trial Update: Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
An ongoing clinical trial by Paragonix Technologies aims to create a global registry to improve donor lung preservation. Enrollment is by in…
-
CLINICAL_TRIALS research · 2025-05-15Clinical Trial Update: Effects of Pulmonary Rehabilitation on Quality of Life and Health in Pulmonary Arterial Hypertension Patients [NA]
A clinical trial is planned to assess the impact of pulmonary rehabilitation on quality of life and health in patients with pulmonary arteri…
-
CLINICAL_TRIALS trial_result · 2025-05-13Clinical Trial Update: Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) [Phase 3]
Phase 3 study of sotatercept in newly diagnosed intermediate- and high-risk pulmonary arterial hypertension has completed.
-
CLINICAL_TRIALS trial_result · 2025-05-07Clinical Trial Update: This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) [Phase 1]
A Phase 1 trial evaluating the safety, tolerability, and preliminary effects of inhaled BAY1237592 in patients with pulmonary arterial hyper…
-
CLINICAL_TRIALS trial_result · 2025-04-27Clinical Trial Update: A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies. [Phase 3]
Phase 3 long-term safety study of macitentan in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertens…
-
CLINICAL_TRIALS research · 2025-04-27Clinical Trial Update: Pulmonary Hemodynamics During Exercise - Research Network
A study evaluating pulmonary hemodynamics during exercise is currently recruiting, sponsored by the Medical University of Graz, focusing on …
-
CLINICAL_TRIALS research · 2025-04-23Clinical Trial Update: PAH Exercise Study [Phase 3]
This update indicates that a Phase 3 clinical trial evaluating exercise therapy for Pulmonary Arterial Hypertension is currently recruiting,…
-
CLINICAL_TRIALS trial_result · 2025-04-22Clinical Trial Update: Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag) [Phase 1]
Phase 1 bioequivalence study comparing Selexipag 400 mcg tablets to Uptravi 400 mcg tablets for pulmonary arterial hypertension has complete…
-
CLINICAL_TRIALS research · 2025-04-08Clinical Trial Update: PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.
A proof-of-concept study is evaluating inhaled targeted imatinib nan formulations for pulmonary arterial hypertension and pulmonary fibrosis…
-
CLINICAL_TRIALS research · 2025-04-08Clinical Trial Update: Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
This clinical trial is evaluating an artificial intelligence–assisted approach for evaluating pulmonary hypertension and related conditions …
-
FDA approval · 2025-04-04FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for LETAIRIS (ambrisentan) from Gilead Sciences, Inc. The approval covers an updated labeling/new in…
-
FDA approval · 2025-04-04FDA Approved: AMBRISENTAN — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for ambrisentan from Apotex Corp., authorizing a generic version of the drug. Ambrisentan is used to…
-
FDA approval · 2025-04-04FDA Approved: AMBRISENTAN — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for ambrisentan submitted by Sun Pharmaceutical Industries, Inc. The action concerns an update t…
-
FDA approval · 2025-04-04FDA Approved: AMBRISENTAN — Supplemental Application (Sigmapharm Laboratories, LLC)
FDA approved a supplemental application for Ambrisentan from Sigmapharm Laboratories, LLC under an ANDA.
-
FDA approval · 2025-04-04FDA Approved: AMBRISENTAN — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for a generic version of ambrisentan, used to treat pulmonary arterial hypertension. Mylan Pharmaceu…
-
FDA approval · 2025-04-04FDA Approved: AMBRISENTAN — Supplemental Application (Cipla USA Inc.)
FDA approved a supplemental application for Ambrisentan from Cipla USA Inc. under ANDA 210715.